AGD and androgen exposure in humans is not well defined. This review focuses on the current evidence for 25 such a relationship. As in rodents, a clear gender difference is detected during fetal development of the AGD 26 in humans which is maintained thereafter. Reduced AGD in association with clinically relevant outcomes of 27 potential environmental exposures, such as cryptorchidism or hypospadias, is in keeping with AGD as a 28 marker of fetal testicular function. Furthermore, AGD may reflect variations in prenatal androgen exposure in 29 healthy children as shorter AGD at birth is associated with reduced masculine play behaviour in preschool 30 boys. Several studies provide evidence linking shorter AGD with lower fertility, semen quality and 31 testosterone levels in selected groups of adults attending andrology clinics. Overall, the observational data in 32 humans are consistent with experimental studies in animals and support the use of AGD as a biomarker of 33 fetal androgen exposure. Future studies evaluating AGD in relation to reproductive hormones in both infants 34 and adults, and to gene polymorphisms, will help to further delineate the effect of prenatal and postnatal 35 androgen exposures on AGD. 36 
Introduction: 37
Links between disorders of male reproductive system, such as reduced semen quality and testicular germ cell 38 tumour (TGCC), as well as genital abnormalities at birth, such as cryptorchidism and hypospadias, are well 39 established (Skakkebaek et al., 2001 ). These observations led to the hypothesis of 'testicular dysgenesis 40 syndrome' (TDS) which proposes that abnormal testis development during fetal life is an important 41 mechanism underlying common disorders of the male reproductive tract which manifest during infancy or 42 adult life (Skakkebaek et al., 2001 ). Experimental animal studies, which used anti-androgens to alter fetal 43 testis development, provide a compelling model to support the hypothesis (Dean and Sharpe, 2013) . Although 44 TGCC, one component of TDS, has not been replicated in animal models, this is perhaps due to species 45 specificity (Juul et al., 2014) . Rare disorders of sex development (DSD) due to a primary defect in testis 46 determination, androgen secretion or androgen action manifest phenotypic features of TDS, supporting the 47 relevance of the TDS model in humans (Hughes et al., 2007) . The early origins of male reproductive disorders 48 hypothesis is of relevance to public health as environmental exposure to potential endocrine disruptors in 49 utero have been proposed to explain the increasing trends in the incidence and their marked geographical 50 variation (Acerini and Hughes, 2006; Hauser et al., 2015) . Estimating the burden of prenatal exposure to 51 potential endocrine disruptors is a challenge, as congenital disorders of the male reproductive tract are 52 relatively rare and disturbed reproductive function is likely to manifest a long time after the chemical 53 exposure. In economic terms, an estimated annual cost to the European Union of 15 billion Euro has been 54 calculated for the consequences of male reproductive disorders (e.g., treatments for infertility, orchidopexies, 55 testis cancer) using the 'Intergovernmental Panel on Climate Change' weight-of-evidence characterization 56 model for probability of causation (Hauser et al., 2015) . 2007). After a surge of LH and testosterone secretion following delivery, testosterone levels decline in the 81 first week of life (Corbier et al., 1990) . Further activation of the hypothalamic-pituitary-gonadal axis known 82 as the mini-puberty, starts at the end of the first week, peaking at 1-3 months of age before declining to low or 83 undetectable levels by 6 months of age (Bergada et al., 2006; Forest et al., 1974; Kuiri-Hanninen et al., 2014) . 84
Subsequently, the axis remains quiescent until the onset of puberty. The observation of a MPW in the rat 85 (equivalent to 8-14 weeks of gestation in the human) suggests that alterations in androgen action during a 86 critical window of fetal development results in TDS and permanent changes in AGD (Welsh et al., 2008) . 87
88

Definition and measurement methods 89
In rodents, AGD is measured from the anus to the posterior base of the genital tubercle (Gallavan et al., 1999) . 90
In contrast to rodents, the external genitalia are well developed at birth in humans with the genital tubercle 91 transformed into the penis in males and clitoris in females. Investigators have used different landmarks to 
Associations between AGD, gender and age in healthy individuals 113
The AGD in rodents is approximately twice as long in males compared to females, and is routinely used to 114 determine sex (Dean and Sharpe, 2013) . We and others have reported that AGD is also sexually dimorphic in 115 humans and displays a similar relative magnitude of difference (male: female ratio ranges from 1.4:1 to 2.2:1) 116 (Table-1 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 . While a longer AGD is associated with a higher sperm 252 count and better semen quality, the strength of association is insufficient to predict male fertility in an 253 individual (Eisenberg and Lipshultz, 2015) . A short AGD does distinguish men with non-obstructive causes of 254 azoospermia (which is associated with TDS) from those with obstructive azoospermia . 255
These findings lend support for AGD as a biomarker for TDS and testis function in selected populations, but, 256 few studies have explored the link between AGD and the larger range in testis size and semen quality in 257 healthy males. A shorter AGD in association with lower semen quality has been reported in a US study of 258 healthy young men (Mendiola et al., 2011) ; however, the results were not replicated in a similar study 259 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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Genetic variations and AGD 275
As previously discussed, establishing a direct link between prenatal androgen exposure and AGD is difficult 276 in humans, and the current evidence has relied mainly on data from observational epidemiological studies. 277
Novel study designs using genes as instruments for causal inferences (i.e., Mendelian Randomisation) as has 278 been applied to the study of cardiovascular disease (Thanassoulis, 2013) shorter AGD when the data were analysed in a stratified model , but this finding was 288 not replicated in another study (Sathyanarayana et al., 2012) . There is an inverse association between the 289 length of the CAG repeats and transcriptional activity of the androgen receptor as measured in vitro 290 (Chamberlain et al., 1994) , and when studied in relation to sperm quality, longer CAG repeats were associated 291
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